Maximizing PK and ADA Evaluation Efficiency Using Cutting-Edge Rabbit Antibody Development Technology
About this webinar
Rabbits possess a robust and unique immune system that generates antibodies with superior specificity, affinity and diversity compared to rodents. This makes them highly recommended for producing high-quality antibodies. In the dynamic field of pharmaceutical development, the need for high precision and rigorous safety validation is critical to ensuring the efficacy and safety of new therapeutics.
Therefore, anti-idiotypic antibodies (anti-ID Abs) play a crucial role in this process by binding to therapeutic drugs in biological fluids, facilitating drug validation and safety evaluation. They are commonly used in pharmacokinetics (PK) and pharmacodynamics (PD) assays to assess drug efficacy and are instrumental in evaluating drug safety through anti-drug antibody (ADA) assays, which measure immunogenicity.
In this webinar, the expert speaker will provide a detailed overview of anti-ID abs, exploring their significance and applications. She will also delve into the reasons why rabbits are the preferred host for generating high-performance anti-ID abs and highlight the advantages that make them ideal for this purpose. Additionally, attendees will gain insights into the advanced techniques and methodologies to optimize the development of these crucial antibodies, enhancing therapeutic and diagnostic outcomes in the biopharmaceutical industry.
Register for this webinar today to discover why rabbits are the preferred choice for generating high-performance anti-ID Abs and learn advanced techniques to optimize antibody development.
Who should attend
- Antibody drug development and gene/cell therapy
- Antibody discovery and engineering
- Gene and cell therapy
- PK/ADA assay
- Biomedical/Clinical Trial Researchers
What you will learn
- The relevance of anti-ID Abs in antibody development
- Why rabbits are the preferred host for generating high-performance anti-ID Abs
- The discovery strategies and capabilities for developing rabbit anti-ID Abs
Featured Speakers
Dr. Hui Foon Tan, PhD
Dr. Hui Foon Tan is a Global Product Manager who supports GenScript antibody production service currently. She graduated with her PhD in Biological Sciences from Nanyang Technological University, Singapore, and continued to work as a Postdoctoral Research Fellow in Cancer Research for another two years.
After she joined GenScript, Dr. Tan has supported the proteins and antibody production services in APAC region for a year. She provides application support for pre- and post-sale activities for services as well as updates and seminars to support co-stakeholders, distributors and customers.
Currently, she is supporting new service launches and training in antibody production services. She also collates market dynamics and competitive market information from the field to understand the global market trends and collaborate with the team.
Partner for this event
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to make people and nature healthier through biotechnology by scripting possibilities.
Related webinars
More from GenScript.
Platform Selection and Development Strategies for High-Performance Anti-Idiotype Antibody Development – in Just 9 Weeks
Advances in mRNA & LNP technology for in vivo CAR‑T therapy
High-Throughput Antibody Workflows for AI-Enabled Process Optimization
Enhancing Prime Editing Efficiency Through Modified pegRNAs
Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA Design
Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development
Optimized Conjugation Solution for Precise Extrahepatic Delivery of Small Nucleic Acid Drug
AI in Molecular Biology: Revolutionizing the Future of Biotech
High-Titer Lentivirus Solutions in 5 Days: Break Production Barriers for CGT
How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround
Advancing Small Nucleic Acid Drug Development with a One-Stop Solution
Solutions for Vaccine Innovation and Gene Therapy: Unlocking the Power of RNA